Low‐dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial

No drug is yet approved to treat the core symptoms of autism spectrum disorder (ASD). Low‐dose suramin was effective in the maternal immune activation and Fragile X mouse models of ASD. The Suramin Autism Treatment‐1 (SAT‐1) trial was a double‐blind, placebo‐controlled, translational pilot study to examine the safety and activity of low‐dose suramin in children with ASD.

[1]  Jonathan Green,et al.  Parent-mediated social communication therapy for young children with autism (PACT): long-term follow-up of a randomised controlled trial , 2016, The Lancet.

[2]  Kefeng Li,et al.  Metabolic features of chronic fatigue syndrome , 2016, Proceedings of the National Academy of Sciences.

[3]  A. Paetau,et al.  Mitochondrial DNA Replication Defects Disturb Cellular dNTP Pools and Remodel One-Carbon Metabolism. , 2016, Cell metabolism.

[4]  Maureen S. Durkin,et al.  Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012 , 2018, Morbidity and mortality weekly report. Surveillance summaries.

[5]  L. Schieve,et al.  Estimated Prevalence of Autism and Other Developmental Disabilities Following Questionnaire Changes in the 2014 National Health Interview Survey. , 2015, National health statistics reports.

[6]  Chris Oliver,et al.  Prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta-analysis. , 2015, The lancet. Psychiatry.

[7]  B. Stoll,et al.  Language outcomes among ELBW infants in early childhood. , 2015, Early human development.

[8]  David S. Wishart,et al.  MetaboAnalyst 3.0—making metabolomics more meaningful , 2015, Nucleic Acids Res..

[9]  Kefeng Li,et al.  Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model , 2015, Molecular Autism.

[10]  R. Schmidt,et al.  Environmental chemical exposures and autism spectrum disorders: a review of the epidemiological evidence. , 2014, Current problems in pediatric and adolescent health care.

[11]  R. Naviaux,et al.  Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy , 2014, Translational Psychiatry.

[12]  R. Naviaux.  Metabolic features of the cell danger response. , 2014, Mitochondrion.

[13]  B. Isakson,et al.  Differentiating connexin hemichannels and pannexin channels in cellular ATP release , 2014, FEBS letters.

[14]  E. Minikel,et al.  Autism Spectrum Disorder Genetics: Diverse Genes with Diverse Clinical Outcomes , 2014, Harvard review of psychiatry.

[15]  G. Burnstock.  Purinergic signalling: from discovery to current developments , 2013, Experimental physiology.

[16]  Janet K. Kern,et al.  A Comparison of the Autism Treatment Evaluation Checklist (ATEC) and the Childhood Autism Rating Scale (CARS) for the Quantitative Evaluation of Autism , 2013, Journal of mental health research in intellectual disabilities.

[17]  R. Naviaux,et al.  Antipurinergic Therapy Corrects the Autism-Like Features in the Poly(IC) Mouse Model , 2013, PloS one.

[18]  J. Mulick,et al.  Comparison of the Leiter International Performance Scale-Revised and the Stanford-Binet Intelligence Scales, 5th Edition, in children with autism spectrum disorders. , 2013, American journal on intellectual and developmental disabilities.

[19]  B. Ryffel,et al.  ATP release and purinergic signaling: a common pathway for particle-mediated inflammasome activation , 2012, Cell Death and Disease.

[20]  R. Naviaux.  Oxidative Shielding or Oxidative Stress? , 2012, Journal of Pharmacology and Experimental Therapeutics.

[21]  S. Edelson,et al.  Autism Treatment Evaluation Checklist , 2012 .

[22]  K. Jacobson,et al.  G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions , 2012, Purinergic Signalling.

[23]  D. Green,et al.  Mitochondria and the Autophagy–Inflammation–Cell Death Axis in Organismal Aging , 2011, Science.

[24]  David Quig,et al.  Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity , 2011, Nutrition & metabolism.

[25]  S. Ghosh,et al.  Mitochondria in innate immune responses , 2011, Nature Reviews Immunology.

[26]  S. Sisó,et al.  Sensory circumventricular organs in health and disease , 2010, Acta Neuropathologica.

[27]  Gary D Bader,et al.  Functional impact of global rare copy number variation in autism spectrum disorders , 2010, Nature.

[28]  D. Moher,et al.  CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials , 2010, Journal of pharmacology & pharmacotherapeutics.

[29]  Takeharu Nagai,et al.  Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators , 2009, Proceedings of the National Academy of Sciences.

[30]  M. Ehrlich,et al.  A Legionella effector acquired from protozoa is involved in sphingolipids metabolism and is targeted to the host cell mitochondria , 2009, Cellular microbiology.

[31]  W. R. Wikoff,et al.  Response and recovery in the plasma metabolome tracks the acute LCMV-induced immune response. , 2009, Journal of proteome research.

[32]  G. Cortopassi,et al.  Inhibition of mitochondrial function induces an integrated stress response in oligodendroglia , 2009, Neurobiology of Disease.

[33]  A. Trautmann.  Extracellular ATP in the Immune System: More Than Just a “Danger Signal” , 2009, Science Signaling.

[34]  R. Naviaux.  Mitochondrial control of epigenetics , 2008, Cancer biology & therapy.

[35]  S. Targum,et al.  The clinical global impressions scale: applying a research tool in clinical practice. , 2007, Psychiatry (Edgmont (Pa. : Township)).

[36]  R. Fields,et al.  Extracellular ATP in activity‐dependent remodeling of the neuromuscular junction , 2007, Developmental neurobiology.

[37]  C. Lord,et al.  The Autism Diagnostic Observation Schedule: Revised Algorithms for Improved Diagnostic Validity , 2007, Journal of autism and developmental disorders.

[38]  G. Burnstock.  Pathophysiology and Therapeutic Potential of Purinergic Signaling , 2006, Pharmacological Reviews.

[39]  David W Gaylor,et al.  Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. , 2004, The American journal of clinical nutrition.

[40]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[41]  C. Stein,et al.  Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. , 1993, Cancer research.

[42]  Lewis B. Sheiner,et al.  Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[43]  F. Hawking.  Concentration of Bayer 205 (Germanin) in Human Blood and Cerebrospinal Fluid after Treatment. , 1940 .

[44]  M. Aman,et al.  Validity of the Aberrant Behavior Checklist in Children with Autism Spectrum Disorder , 2014, Journal of autism and developmental disorders.

[45]  I. Hertz-Picciotto,et al.  Is Maternal Influenza or Fever During Pregnancy Associated with Autism or Developmental Delays? Results from the CHARGE (CHildhood Autism Risks from Genetics and Environment) Study , 2012, Journal of Autism and Developmental Disorders.

[46]  H. McConachie,et al.  Validation of the repetitive behaviour questionnaire for use with children with autism spectrum disorder , 2012 .

[47]  G. Antes,et al.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials , 2011 .

[48]  D. Wallace,et al.  Energetics, epigenetics, mitochondrial genetics. , 2010, Mitochondrion.

[49]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.

[50]  F. Hawking.  Suramin: with special reference to onchocerciasis. , 1978, Advances in pharmacology and chemotherapy.